Latest news with #INCY
Business Insider
5 days ago
- Business
- Business Insider
Evercore ISI Reaffirms Their Hold Rating on Incyte (INCY)
Evercore ISI analyst maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $73.00. The company's shares closed yesterday at $67.42. Confident Investing Starts Here: In addition to Evercore ISI, Incyte also received a Hold from William Blair's Matt Phipps in a report issued yesterday. However, on the same day, BMO Capital maintained a Sell rating on Incyte (NASDAQ: INCY). Based on Incyte's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.05 billion and a net profit of $158.2 million. In comparison, last year the company earned a revenue of $880.89 million and had a net profit of $169.55 million Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Earlier this month, Thomas Tray, the CAO of INCY sold 1,614.00 shares for a total of $105,515.61.
Business Insider
15-05-2025
- Business
- Business Insider
Incyte (INCY) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Incyte (INCY – Research Report) yesterday and set a price target of $89.00. The company's shares closed yesterday at $61.16. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. According to TipRanks, Ahmad has an average return of -5.3% and a 43.00% success rate on recommended stocks. In addition to Bank of America Securities, Incyte also received a Buy from TD Cowen's Marc Frahm in a report issued on April 29. However, on May 13, RBC Capital maintained a Hold rating on Incyte (NASDAQ: INCY). INCY market cap is currently $11.78B and has a P/E ratio of 188.15. Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year. Most recently, in March 2025, Barry Flannelly, the EVP & General Manager US of INCY sold 19,807.00 shares for a total of $1,340,655.93.
CNBC
14-05-2025
- Business
- CNBC
These 3 stocks are showing clear bottoming formations and could rip higher, charts show
What do Incyte , KKR and Chipotle have in common? At first glance, absolutely nothing. INCY is a biotech stock, KKR is a financial/private equity firm and CMG is, of course, a popular restaurant in the consumer discretionary sector. If you haven't heard much about these names during the market's recent surge, it's no surprise. All three remain below their respective 200-day moving averages, which means they've underperformed in recent weeks. This is especially glaring compared to large-cap growth stocks, many of which have rallied 20%, 30%, 40% from their lows. Some are even approaching new highs for the year. Conversely, these three stocks are still well off their peaks. So, if we were to run a simple relative strength screen focused only on stocks near their highs, we'd completely overlook them. That said, we can't ignore stocks like this. If this market is going to extend meaningfully higher, participation will likely need to broaden beyond the current leaders. A hallmark of a strong uptrend is rotation — capital flowing into laggards as the front-runners become near-term overbought. And that rotation often begins with names showing clear bottoming formations, despite underperforming. Believe it or not, as of this morning, more than half of S & P 500 stocks are still trading below their 200-day moving averages. So, relying solely on trend-following screens would eliminate a lot of potentially actionable setups. We're highlighting INCY, KKR and CMG because each has traced out a textbook bottoming pattern over the last few weeks — in particular, an inverse head and shoulders formation. KKR broke out earlier this week, a move that it now will be trying to extend. We're still waiting for INCY and CMG to do the same. Both are close to their respective potential breakout zones. These patterns may or may not trigger, but the process remains the same: focus on identifying technically attractive setups with clear upside potential If the breakouts hold, the measured move targets on all three names would put them above their 200-day moving averages. And if that happened, it would be a meaningful development, and potentially a signal of broader participation beneath the surface. As we often say, one of the earliest signs of a long uptrend is seeing successful bullish patterns. Again, the formations don't have to be large to be effective. Some of the smallest, cleanest bases often precede bigger formations, creating the kind of solid foundation that fuels sustainable rallies. These three stocks are just examples of the types of setups we'll continue to look for as the market pushes higher. The goal is to stay aligned with names breaking out from clear bases — without chasing those that are already stretched. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
13-05-2025
- Business
- Yahoo
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts' consensus estimates. Is now the time to buy INCY? Find out in our full research report (it's free). Revenue: $1.05 billion vs analyst estimates of $989.2 million (19.5% year-on-year growth, 6.4% beat) Adjusted EPS: $1.16 vs analyst estimates of $1.05 (10.6% beat) Adjusted EBITDA: $227.5 million vs analyst estimates of $279.3 million (21.6% margin, 18.5% miss) Operating Margin: 19.5%, up from 10.4% in the same quarter last year Free Cash Flow Margin: 27.9%, up from 23.8% in the same quarter last year Market Capitalization: $11.78 billion Incyte's first quarter results reflected notable commercial momentum and pipeline advancement, with management attributing much of the company's performance to strong demand for Jakafi and the initial launch of Niktimvo. CEO Herve Hoppenot highlighted the successful rollout of Niktimvo in chronic graft-versus-host disease, as well as ongoing growth in Jakafi's polycythemia vera indication. Management also emphasized the positive impact of expanded formulary coverage for Opzelura, now preferred on two of the three largest pharmacy benefit manager formularies, resulting in broader patient access and higher net product revenue. Looking ahead, Incyte's leadership outlined several key revenue drivers. Hoppenot pointed to three additional planned product launches in 2025, continued progress in late-stage clinical studies, and several pivotal data readouts as critical to sustaining growth. CFO Christiana Stamoulis reaffirmed increased full-year guidance for Jakafi, citing favorable gross-to-net dynamics and persistent patient demand. Management also addressed tariff concerns, stating that dual US and European manufacturing provides flexibility, minimizing potential impacts from trade policy changes. Incyte's management detailed a quarter shaped by strong product demand, expanding market access, and pipeline milestones. Key topics included new product launches, growth in core franchises, and the impact of healthcare policy changes. Jakafi growth in polycythemia vera: Management cited robust volume increases for Jakafi, especially in the polycythemia vera indication, supported by early intervention data and effective physician education campaigns. They expect polycythemia vera to become the largest driver for Jakafi over time. Opzelura's expanded access: The addition of Opzelura to Optum Premium's preferred formulary improved its commercial coverage to 94%, enhancing growth prospects for both atopic dermatitis and vitiligo indications. Niktimvo launch momentum: The launch of Niktimvo for chronic graft-versus-host disease exceeded initial expectations, with rapid uptake across leading bone marrow transplant centers. Management noted that 95% of top centers have used the product. Pipeline data readouts: Positive phase 2 and phase 3 clinical data for pipeline assets such as povorcitinib in hidradenitis suppurativa and chronic spontaneous urticaria were highlighted, with management aiming for three additional product launches in 2025. Tariff risk mitigation: Management explained that dual sourcing and geographically diversified manufacturing reduce the impact of potential pharmaceutical tariffs, while inventory levels for at-risk inputs remain sufficient to support near-term supply needs. Management's outlook for the next several quarters focuses on continued product launches, new clinical data, and operational efficiency as the main themes underpinning future performance. Multiple product launches ahead: The company expects three more launches in 2025, which management believes will materially expand the commercial portfolio and near-term revenue base. Advancing pipeline milestones: Several late-stage and pivotal clinical trials are on track for readouts this year, including phase 3 studies in dermatology and oncology, which could broaden Incyte's approved indications and market reach. Operational flexibility and risk management: Diversified manufacturing and inventory strategies are expected to safeguard supply continuity, while management cited ongoing investments in R&D and commercial infrastructure as essential for long-term growth. Michael Schmidt (Guggenheim): Asked how much Jakafi's polycythemia vera growth is driven by new patient starts versus ongoing therapy; management noted both contribute, with new patient education and persistence supporting future expansion. David Lebowitz (Citi): Inquired about povorcitinib's positioning in chronic spontaneous urticaria relative to biologics; management responded it could serve both pre- and post-biologic patient populations, with some preferring an oral option first. Salveen Richter (Goldman Sachs): Sought details on Opzelura's growth by indication and steps to improve access for atopic dermatitis; management described stable growth across both indications and ongoing efforts to expand formulary coverage and patient support services. Jessica Fye (JPMorgan): Asked about capital allocation and the potential for further share repurchases; management emphasized prioritizing pipeline investment, with business development focused on early-stage partnerships. Madeline (William Blair): Queried whether positive phase 2 data in chronic spontaneous urticaria alters Incyte's plans for other related programs; management noted satisfaction with current pipeline progress, with no plans to restart previously discontinued programs. In the coming quarters, the StockStory team will be monitoring (1) the pace and breadth of new product launches and their initial market adoption, (2) the timing and outcome of late-stage clinical data readouts, particularly in dermatology and oncology, and (3) the continued expansion of commercial coverage for Opzelura and other key products. Execution on these initiatives, along with effective supply chain management amid evolving tariff risks, will be critical for tracking Incyte's strategic progress. Incyte currently trades at a forward P/E ratio of 10.3×. Should you load up, cash out, or stay put? The answer lies in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-04-2025
- Business
- Yahoo
3 Reasons INCY is Risky and 1 Stock to Buy Instead
Over the past six months, Incyte's shares (currently trading at $60.02) have posted a disappointing 11.8% loss while the S&P 500 was down 1.7%. This was partly driven by its softer quarterly results and might have investors contemplating their next move. Is there a buying opportunity in Incyte, or does it present a risk to your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free. Even though the stock has become cheaper, we don't have much confidence in Incyte. Here are three reasons why there are better opportunities than INCY and a stock we'd rather own. Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases. Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes. Analyzing the trend in its profitability, Incyte's adjusted operating margin decreased by 13.9 percentage points over the last two years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. Its adjusted operating margin for the trailing 12 months was 9.8%. Analyzing the long-term change in earnings per share (EPS) shows whether a company's incremental sales were profitable – for example, revenue could be inflated through excessive spending on advertising and promotions. Sadly for Incyte, its EPS declined by 14.8% annually over the last five years while its revenue grew by 14.5%. This tells us the company became less profitable on a per-share basis as it expanded. A company's ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity). We like to invest in businesses with high returns, but the trend in a company's ROIC is what often surprises the market and moves the stock price. Over the last few years, Incyte's ROIC has unfortunately decreased significantly. We like what management has done in the past, but its declining returns are perhaps a symptom of fewer profitable growth opportunities. Incyte isn't a terrible business, but it isn't one of our picks. After the recent drawdown, the stock trades at 10.4× forward price-to-earnings (or $60.02 per share). This valuation multiple is fair, but we don't have much faith in the company. We're pretty confident there are superior stocks to buy right now. We'd recommend looking at a dominant Aerospace business that has perfected its M&A strategy. The Trump trade may have passed, but rates are still dropping and inflation is still cooling. Opportunities are ripe for those ready to act - and we're here to help you pick them. Get started by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today for free.
